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Abstract
Background: This article presents the qualitative component linked to a larger study of implementation of the
Xpert™ MTB/Rif technology in two Brazilian cities. Despite intrinsic advantages of new health technologies, its
introduction can be disruptive to existing routines, and it is thus important to understand how these innovations
are perceived by the different groups involved in its regular use.
Methods: This study was based on semi-structured interviews with patients, lab technicians, health care workers
and managers involved with diagnosis and care of Tuberculosis (TB). The interviews had their content analyzed in
order to abstract the different perspectives for the various actors.
Results: For patients the changes were not perceived as significant, since their greatest concerns were related to
treatment and the stigma associated with TB. The professionals in general welcomed the new technique, which
dramatically decreases the workload, time and reliability of diagnosis, in their view. However, we noted difficulties
with the concomitant implementation of new IT technology for recording and reporting test results, which
negatively impacted the time necessary to get lab diagnosis to physicians.
Conclusions: Through this analysis we detected some bottlenecks in the surrounding environment, not necessarily
linked to the technology itself but which could hamper considerably its advantages.
Keywords: Tuberculosis, Diagnosis, Qualitative research
Background
Tuberculosis (TB) is a curable disease with high treat-
ment success rates. Nevertheless, it figures among the
top ten causes of death worldwide, with 9.4 million new
cases and 1.68 million deaths in 2009, 380,000 of which
occurred in HIV-positive individuals. The emergence of
drug-resistant forms of TB, particular to rifampin, a
highly effective drug used worldwide, and their rapid
spread in Asian, African and East European countries
are a particular concern [1].
Early detection of both the sensitive and resistant forms
of the disease reduces loss in quality of life, morbidity,
deaths and prevents the transmission of drug sensitive and
resistant TB. However, a major obstacle in the control of
TB is the delay in diagnosis. The provision of diagnostic
services is inadequate due to the organization and infra-
structure of the health services network, and to limitations
of the technologies currently used, such as sputum smear
and culture for Mycobacterium tuberculosis (MTB). The
sensitivity of the former is low (especially among patients
with HIV co-infection and children) and requires two
patient visits to the clinic to provide the material: at least
two samples are required to attain optimal, yet very low,
sensitivity (around 70 %). Sensitivity of smears is even lower
in paucibacillary forms of pulmonary disease, as in children
and in patients infected with TB and HI. It should be noted
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R. de Camargothat sputum smear is a fully manual, labor-
intensive process whose quality is entirely dependent on
technicians’ expertise, and fluctuations in the processing
influence heavily the test’s diagnostic properties. Sensitivity
of culture is over 90 %, but long delays in providing results
reduce its applicability for rapid medical decision and
infrastructure bottlenecks hamper its wide availability in
developing countries [2].
Brazil is among the 22 countries with the highest TB
burden. The estimate by World Health Organization
(WHO) for 2011 was 91,000 new cases and 4,900 deaths
in the country [1]. Th diagnosis of pulmonary TB in Brazil
relies almost exclusively on sputum smears, offered free of
charge by the national health care system (Sistema Único
de Saúde, or SUS). The National TB Control Program
(Programa Nacional de Controle da Tuberculose – PNCT)
recommends the use of culture (and drug sensitivity tests
if appropriate) for diagnosing TB when specimens are
difficult to obtain, in cases with a high probability of
resistance and in those with usual negative smears [3]. In
practice, Brazil has more than one third of new TB cases
reported without bacteriological confirmation. It is
estimated that 20 % of them do not represent true cases of
TB, which means delay in correct diagnosis and unneces-
sary exposure to the risk of liver toxicity and other adverse
effects from tuberculostatics [4, 5]. On the other hand, the
WHO estimates that only 79 % of new and relapsed cases
are detected in Brazil [1], leaving a considerable number
of patients without proper care and hindering the control
of the disease in the country.
After a century of virtual stagnation, new technologies
for the detection of MTB are being developed, mostly
based on molecular methods. One of these new technolo-
gies is the automated polymerase chain reaction-based
test Xpert™ MTB/Rif, for the rapid detection of MTB and
rifampicin resistance. The new test has been considered a
milestone for the global control of TB, because of its high
sensitivity and specificity both for detecting MTB and
resistance to rifampin [2], as well as its ability to deliver
results in less than two hours. In December 2010, the
WHO recommended the adoption of the Xpert™ MTB/Rif
[6]. The Brazilian Ministry of Health approved the incorp-
oration of this method in March 2013, after an implemen-
tation pilot study in two high TB-incidence cities, Manaus
and Rio de Janeiro.
The GeneXpert ™ MTB/Rif test performed on the
GeneXpert ™ MTB/Rif system is a rapid molecular test for
the detection of MTB and rifampicin resistance. It consists
of a GeneXpert instrument, personal computer and net
disposable cartridges. The system combines sample prep-
aration in cartridges and the amplification and detection
of nucleic acid DN in a fully integrated and automated
instrument for analysis (Fig. 1).
The test is based on the polymerase chain reaction
(PCR). A number of molecular beacons are used simultan-
eously to detect the presence of MTB and to diagnose
Fig 1 Operating cycle of the GeneXpert™ MTB/Rif equipment
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rifampicin resistance as a surrogate marker for multidrug
resistant disease. Species-specific primers allow the amplifi-
cation of the rpoB central region of MTB DNA. Nested
PCR is used to increase the sensitivity of the assay. The
manual pre-treatment of the sample for the test comprises
the following steps: the technician adds the buffer to
sputum samples and a defined volume of this mixture is
transferred to the sample chamber of the cartridge, which
is then inserted into the instrument. From this point, all
steps are automated: the GeneXpert ™ first catches the
MTB organisms from the sputum sample in a filtering
membrane. The inhibitors are then washed away from the
captured cells with the buffer solution. Finally, captured
cells are washed and lysed with ultrasonic energy and the
released DNA is eluted through the filter membrane. The
DNA solution is finally mixed with dried PCR reagents and
transferred to the PCR tube for PCR and real-time detec-
tion. The cartridges are disposable and contain: i) cham-
bers to maintain the samples and reagents; ii) a valve body
comprising a piston and syringe; iii) a rotary valve system
to control the movement of fluids between chambers; iv)
an area for cell capturing, concentrating, washing and
lysis; v) lyophilized reagents of real time PCR buffer and
wash solutions; and vi) An integrated PCR reaction tube
which is filled automatically by the instrument. The total
processing time is 1 h and 45 min.
There has been a recent increase in the literature on in-
novations in health [7–10], which points out that the
process of diffusion of new technologies within health care
systems is complex and determined by multiple factors that
can hamper or facilitate their adoption. Innovations in
health – new technologies, new services and/or processes –
are usually implemented with the goal of having better
outcomes, more managerial effectiveness, increase cost-
effectiveness or users’ experience, or any combination of
those. Despite any putative advantages, however, the intro-
duction of new technologies can be disruptive of established
professional roles and processes, especially in the case of
TB in which diagnostic routines have remained unchanged
for decades. This can elicit various forms of resistance from
the different actors involved in the process, and if that does
happen, the new technology will operate at a sub-optimal
level (if at all), without granting its full benefits to the
various professionals and patients depending on it [11–13].
A better understanding of the elements that can
influence and shape the adoption of this new technology
will help the effort to introduce the test in the clinical
practice and health care facilities in the country, and,
consequently, contribute to the control of the disease.
The goal of this study is, thus, to qualitatively evaluate
the repercussions of the adoption of the Xpert™ MTB/
Rif in the Brazilian Health System from the perspective
of patients, health professionals and managers, consider-
ing aspects such as understanding, perception and
meaning that usually are not easily amenable to quanti-
tative approaches.
Methods
The present study was a component of a larger implemen-
tation study, and the sites for the collection of empirical
data were healthcare facilities in two Brazilian cities with
high burdens of TB (Rio de Janeiro and Manaus), where
the implementation study was carried out. We chose two
of the ten selected areas in Rio de Janeiro, and an additional
site in Manaus, according to criteria of accessibility and
implementation of the new technology. The pilot imple-
mentation study was conducted in labs serving the primary
care network covering the vast majority of new TB cases in
both cities. The focus on primary care facilities was deter-
mined by the NTCP and local health authorities, consider-
ing the eventual applicability of this technology in the
Brazilian context. In the city of Rio de Janeiro, the field sites
for the qualitative research were a family clinic and a
polyclinic. In Manaus, the chosen site was a polyclinic,
which serves as a reference center for TB care in the city.
The qualitative component encompassed three perspec-
tives: patients, healthcare professionals and managers.
The patients’ perspective
Two sets of interviews were conducted with patients
referred for diagnostic procedures for TB, the first set with
patients whose diagnoses were based on smears and the
others with patients diagnosed after the introduction of the
Xpert™ MTB/Rif technology. Patients were interviewed
after a visit to the TB clinic.
We used a variation of the traditional in-depth inter-
view, a semi-structured interview; in those, the interviewer
has in mind a set of topics that (s)he intends to be
addressed by the interviewee, but they are not formulated
as questions, and do not have a rigid sequence. As the
conversation flows, the interviewer will attempt, with
minimal disruption, to cover the topics [14]. The interview
is a process of producing a shared narrative between inter-
viewer and interviewee [15], and caution must be taken
not to induce responses that would cater to what they
suppose interviewers might be interested in hearing. Thus,
we selected trained interviewers with previous experience
in this methodology, which were instructed to indirectly
approach the issues we wanted to address. Three inter-
viewers conducted the interviews, under the direct super-
vision of one of the authors throughout the fieldwork.
The interviews were recorded and transcribed. There
was no preset number of respondents, the necessary
number of interviews was established by the saturation
criterion, “when new data appear to add little to the un-
derstanding of the phenomenon, at least in terms of
how it applies to the material investigated” [16] p65. Thus,
no other patients were recruited when new interviews
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ceased to add new information about what was being
sought in the study.
In Rio de Janeiro, eleven patients diagnosed with
smears (6 men and 5 women with ages ranging 20–58
years) and nine diagnosed with Xpert™ MTB/Rif (5 men
and 4 women with ages ranging 16–59 years) were inter-
viewed. In Manaus, ten interviews were conducted with
patients diagnosed with the new technology (5 men and
4 women with ages ranging 19–85 years). We did not
interview patients diagnosed with smears in Manaus,
since at the time of the fieldwork the new technology
was fully implemented in the clinic.
The following outline of issues were addressed:
 Description of the steps to get to the clinic,
identifying hurdles (queuing, scheduling, difficulties
leaving the workplace);
 Views on TB and its consequences;
 Expectations regarding the diagnostic process;
 Assessment of how the diagnostic process was
handled to this point;
 Main concerns and worries.
The healthcare professionals’ perspective
We used a modified version of a technique developed by
Merhy and Franco [17], the diagnostic flowchart, a spe-
cialized form of group interview. This technique is akin
to a focus group, but the task that the group is required
to discuss, in the original formulation, is the trajectory
of patients within a specific health care service; in our
case, we adapted this to discuss the trajectory of test
samples and results. It should be noted that although
the explicit objective of the group is to produce a flow-
chart, the actual dynamics of their interaction is what is
really relevant. The process of discussion often results in
bringing to the forefront all sorts of issues that are usu-
ally dealt without reflection, that are taken for granted,
but may have great importance in the daily operation.
All professionals involved in the process were gathered
and they were invited to draw up, with the help of a fa-
cilitator, a flowchart that describes the steps the patient
takes once it enters the unit, tracing them all the way to
the end of the diagnostic process. In this case, it was
adapted to include the intralaboratorial steps, retracing
all the way down to the formulation of a final laborator-
ial diagnosis.
Two flowcharts were traced on each site, one regard-
ing workflow before and one after the introduction of
the new technique. During the preparation of the flow-
chart, the conversation with the team was also recorded,
and this material was analyzed in the same way as the
interviews.
At the Rio de Janeiro site, a physician, a nurse, a la-
boratory technician and an administrative staff member
were involved in the preparation of the flowcharts. In
Manaus, the director of the facility, one municipal health
official, a physician, two nurses, a receptionist and a lab
technician participated. The three field researchers par-
ticipated in all the group meetings to elaborate the
flowcharts.
The managers’ perspective
We interviewed key informants at the research sites and
higher-ranking positions of local health departments.
They were interviewed after the introduction of the new
technology.
The interviews were focused on the evaluation of the re-
spondents about what has changed, what would be, in
their opinion, the pros and cons of the new process and
how they viewed the prospect of its expansion within the
SUS. In Rio de Janeiro, the interviews were conducted
with officers in two senior positions at the city’s health de-
partment, two laboratory directors and two officers of the
facilities that served as research sites. In Manaus, three
managers were interviewed: the director of the Polyclinic,
a city health officer and a state health officer.
All transcripts were subjected to a content analysis
[18] as a means to reduce and structure a large unstruc-
tured textual body. The text corpus was read looking for
recurrences within the text and developing coding cat-
egories that could be applied to similar segments of text.
Text segments coded in the same way produced syn-
thetic aggregates and summaries were produced from
such groups.
The flowcharts were compared, with emphasis on a
before/after analysis, seeking to identify the changes pro-
duced by the introduction of the new technology in the
laboratory workflow. The recorded material added an
evaluative dimension to these changes, providing infor-
mation on how the professionals see such changes.
The study was approved by the National (CONEP,
#494/2011) and local Ethical Boards (CEP SMS # 236/11
and CEP FMT/HVD, no number, dated November 24,
2011). All participants signed an informed consent.
None of the subjects selected for the interviews refused
to participate in the study, although this option was
clearly presented as available in the terms of the in-
formed consent. To protect the identity of respondents,
we used fictitious names for patients; managers were
identified by numbers.
Results
The collected data and its analysis provided a rich over-
view of the impact of introducing this new diagnostic
approach in the settings of the study. We only report the
most relevant aspects of our findings.
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The patients’s perspective
The codes used in the content analysis of the interviews
were as follows:
 access to the facility: descriptions of how they got to
the health facilities, difficulties and obstacles
encountered;
 access within the facility: narratives about the
reception and stay within the health facilities;
 trajectory within the health care system: general
information on their experience with the health care
system related to current diagnosis until the
possibility of TB was first raised;
 diagnostic communication : how the diagnosis was
communicated, who communicated and reactions
to it;
 prior knowledge: information and (mis) conceptions
about tuberculosis prior to getting the diagnosis;
 stigma and discrimination: narratives about
situations of perceived discrimination, cultural
representations of stigma, local and family lore
about the disease;
 concerns: main worries related to the disease
The main concerns presented by the patients were re-
lated to the treatment (because of its long duration and
some of the side effects of the drugs) and the persistent
stigma attached to TB, as illustrated by interview ex-
cerpts below. What kind of technology was used for
diagnostic was not their concern, and this issue was not
highlighted by interviewees. Knowledge about different
aspects of the disease was scarce among the inter-
viewees, even though they all already had been diag-
nosed, and there were indications that they knew even
less prior to diagnosis.
Access to the health facility was not an issue for most
patients in all sites, although in Manaus, due to diagnos-
tic activities being concentrated at the site of the field-
work, patients residing in areas distant from the city
center had to face long trips by bus. Most of the patients
were on a medical leave due to the disease, and had their
bus tickets subsidized, so the additional time was not an
issue, although it could become one in case any of these
conditions change.
The interviews reveal a strong stigma associated with
the disease. Interviewees often reported that they omit-
ted the diagnostic from their friends, neighbors and
work colleagues for fear of social exclusion:
“In the street where I live, if people know that [I
have TB], my dear, we would become celebrities.
Everyone would talk [about that]! There would be so
much gossiping that no one would come near [us]!”
(Lucia, Rio)
“I would rather have another type of disease, that
were not transmitted, because just from hearing about
it, people walk away!” (Marta, Rio)
“I didn’t tell anyone, the only people who know are
the folks at home. In the company I work, I’m on
leave, I told it was my backbone.” (Luiz, Manaus)
“I prefer to stay away from people, so that no one will
laugh [at me].” (Fatima, Manaus)
Other accounts mention a link of the diagnosis to be-
ing dirty and impure, or shameful.
“I didn’t want to tell anyone because it felt as if I was
dirty. I thought it was a dirty disease. Like…, an ugly
thing.” (Joyce, Ri)
“First it’s a sensation of, like, shame, that you feel”
(Maíra, Manaus)
The healthcare professionals’ perspective
Analysis of the flowcharts
We found two considerably different situations in Rio de
Janeiro and Manaus, much possibly related to the more
recent (and somewhat incomplete, at the time of the
field work) implementation of the new technology in the
former city. Figures 2 and 3 show the flowcharts for the
old and new technologies in Rio, respectively, as an illus-
tration of the flowcharts produced.
Two issues stood out in the implementation of the
new technology at the Rio de Janeiro site: the changes in
workflow in the laboratory and the concomitant deploy-
ment of the laboratory information system, known by
the acronym GAL, whereas those steps were not con-
comitant in Manaus.
With the previously current technology (smears), the
lab technician is in charge of all stages of the procedure:
sample preparation and analysis, and data entering in
the internal information system. The introduction of the
Xpert™ MTB/Rif introduces a new element, a decision
process that did not previously exist. The technicians
need to analyze the quality of the sample (not all sam-
ples are adequate for the Xpert™ MTB/Rif processing),
and depending on that analysis different procedures will
be adopted. They work with two methods concomi-
tantly: the Xpert™ MTB/Rif and smears (in the case of
inadequate or insufficient samples for Xpert™ MTB/Rif
processing and when the Xpert™ MTB/Rif yielded posi-
tive results, a procedure used in the pilot study protocol
happening at the time of the fieldwork). Consider the ex-
change below between a lab technician (T) and one of
the field researchers (R1) durign the elaboration of the
flowchart in Rio:
“T: If yes, then we have to know if the sample is
adequate for analysis. I do not know if you will write
this, but you have to know if it has enough volume …
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R1: Okay, so, another question: is there enough
volume? Before you did not do that?
T: You must have a minimum volume to make
the smear, but is much smaller than for the
Gene[XPert].
R1: Do you have enough volume? Then what?
T: Then, if so, what does the sample look like? If
there is some food residue, you can’t use it to do it
with the Gene[XPert]. If there are hemoptoics, OK,
with blood residue, you can’t use the Gene[XPert]
either. So there are two constraints like that …
R1: So I’ll change the question: Are there
restrictions?
T: If there is food residue, if there is blood residue,
and volume less than 1 ml… (…)
T: It’s a change. So that created a moment of decision
that did not exist.
R1: Which is important…
T: This was created, a moment of decision that did
not exist. Which method I will use? I’m going to do
the smear or what I’ll do is… the GeneXpert?
R1: Is it the lab technician that decides it on the fly?
T: Yeah, it’s the technician who decides. Did it
generate more work? Because you’re working with
two methods instead of one.”
Additionally, the studied site chose to assign to a
member of the administrative staff the task of entering
data in the GAL system.
There was no noticeable resistance or difficulty posed
by the lab technicians to the new technology. They
referred to it just as a “change in the works”. One
possible explanation for this acceptance is the fact that
the lab technicians have not lost their relevance in the
workflow. They are charged with deciding which tech-
nology is the most appropriate for the analysis of the
sample, in the case of the Xpert MTB/Rif they prepare
samples and operate the instrument, and with the
smears they still perform the usual procedure. In
addition to that, they are still in charge of the internal
registration procedures and of authorizing the delivery
of the diagnostic results.
Regarding the time the procedure takes in the labora-
tory, the technicians claim that there are no significant
differences.
According to their discussion, the difference in time is
mostly in reference to how quickly results are delivered.
The rollout of the GAL, despite being yet a new technol-
ogy under implementation, created greater speed and effi-
ciency in the information system for lab results. Although
the deployment of this information system has led to a
speedier dissemination of the results to physicians, most
of these professionals do not use this system in the labora-
tory facilities, lacking familiarity with the internet and
computer use. There was only one exception, among the
family doctors linked to the facility who regularly accessed
the GAL: a team composed of younger physicians.
Fig 2 Flowchart of the old technology
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Additionally, not all health facilities in the public sys-
tem have the necessary equipment to access the GAL
system (computers and/or internet). Some still need to
contact the lab secretary to get test results.
Still regarding the information system, we identified
several systems present in the unit, besides GAL: a vir-
tual internal parallel information system, patient record
files (on paper), information from community health
workers on patients’ treatments, stored in shoeboxes,
and the lab technicians’ record notebook, with notifica-
tions of samples and test results.
The main issue that stood out in the rollout of the
new technology at the Manaus facility was the change in
the workflow within the laboratory. With the smear mi-
croscopy, the work process involved the preparation and
reading of two samples per user. The process of prepar-
ation and reading a single slide lasts around 30 min.
Workers reported that the job was a routine that in-
volved contact with an abrasive substance, foul odors,
and poor ergonomic conditions, as they spent their shifts
hunched over microscopes. Conversely, with the new
technology, technicians prepare the samples for inserting
them in the instrument. The preparation time is about
15 min. At the facilities participating in this study, each
instrument works simultaneously with four samples. At
the site in Manaus there are two instruments in oper-
ation. As the instruments do their processing, the la-
boratory technicians are dedicated to other activities,
such as smear control and HIV testing. This can be seen
in the exchange below, from the Manaus session (P is a
physician, T a lab technician, R1 is one of the field
researchers):
P: Look, the routine is like this. 15 min, you wait, put
in the machine. Then, when it strikes 1 h and 45, the
lab people returns about 15 min before reading the
result to begin preparing the second batch of
samples.
T: Yeah, we do not waste time.
P: You can not prepare it much earlier, has to be
15 min. Then you have to wait 15 min. Then, when
that sample is finished, take one and put the other.
Then, you wait a further 1 h and 45 to start preparing
other samples.
L: Yeah, that’s how we do it.
Fig 3 Flowchart of the new technology
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P: In these intervals, they will do the control smears,
have a snack.
R1: They get time to do other things. So, the
additional time they get, they get ahead with the
control smears… got it.”
Finally, the lab workers reported that the implementa-
tion of the new technology has had a very positive
impact on the improvement of working conditions in
the laboratory. They do not have to constantly deal with
fire, nor with foul odors. The ergonomic conditions
improved considerably since the technicians do not need
to spend their day poring over microscopes. Another
fragment from Manaus illustrates this (P is a physician,
R1 one of the field researchers):
“P: And for the smear, they used to spend the whole
morning there burning that thing, that awful smell,
and all afternoon on a microscope with a heck of a
back pain, take out a slide, put another slide in…
R1: So, look, when a technician puts the samples on
the machine, we have to make an observation: there is
spare time to do the control smear and… [person] is
talking about something important because in
addition to having spare to make the control smear
and then, balancing the process, you have better
working conditions, because of the things that wear
down the worker, like the smell… better working
conditions, let’s put it this way.
P: Because there, they spend a whole morning with
that dye, that awful fire, that bad smell…
R1: There’s temperature, smell, ergonomic
performance…
M: And the whole afternoon reading slides with no
rest. Take out one, put another in, right? 3
microscopes, 3 persons reading slides with no
interruptions…
M: Sitting 4 h, on a microscope, reading slides, it is a
heck of a back pain.”
As in Rio de Janeiro, a member of the administrative
staff was assigned the task of entering data in the GAL.
The managers’ perspective
The codes used in the content analysis of the interviews
were as follows:
 pros: the perceived advantages of the new
technology;
 cons: the perceived problems with the new technology;
 changes: what were the major changes detected by
the managers;
 sustainability: how they evaluated the perspectives of
widespread and continued use of the new
technology in the public health care system.
Managers interviewed considered the technology itself
mostly in positive terms, but expressed concerns related
to sustainability and the rollout of the information
system to ensure its benefits. Among the positive points
mentioned, the addition of rifampicin resistance detec-
tion, the accuracy and reliability of the results, the less
burdensome processes for lab workers and shorter time
to an accurate results were consistently highlighted.
Negative aspects or reasons for concern were mostly
related to the efficiency of the health system and its abil-
ity to make the most of the new technology considering
the need for better data management, ensure adequate
maintenance and sustainability and full rollout of the
GAL system. The general perception was that, despite
the changes required, the workflow and the manage-
ment of samples between labs and care facilities were
not significantly disrupted and adaptations to the new
method were swift.
The pros of the new technology
The managers pointed out several aspects in favor of the
new technology. The ability to identify resistance to ri-
fampicin was unanimously praised by respondents:
“It is a more qualified result, we can identify rifampicin
resistance in that patient. This also means that
tuberculosis patients’ care will be quicker and more
qualified by the health care staff.” (Manager 2, Rio).
“The diagnosis also informs you on the issue of
resistance to rifampicin. Upon learning that the
patient is already resistant to rifampin, this helps with
the issue of patient severity, because the orientation of
the Ministry of Health is that, if it’s resistant, we’ll
wait for the old culture method, all that…” (Manager
3, Manaus)
Another issue highlighted was the reliability of the
technology, providing the most accurate diagnoses:
“Its reliability is total. It’s out of this world! It is
something magical! In the period from August 3rd to
25th, we performed 304 exams with the ‘Gene’ and
34 tested positive. Of these 34 positive samples, all
were tested by smear, around six slides were
negative. That is, these patients would pass right
through and would continue to spread the disease.”
(Manager 3, Rio)
“The test has a higher sensitivity, higher specificity, so
we better qualify the diagnosis of tuberculosis.”
(Manager 2, Manaus)
One respondent pointed out the importance of the
new technology in the control of the workflow in the
laboratory:
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“The machine also has its importance from the point
of view of monitoring, auditing what happens inside
the lab. With smears, you did not know what was
going on. I mean in quality, errors if the technique is
being done properly.” (Manager 1, Rio)
The satisfaction of the professionals working in the
area was cited by all respondents in Manaus:
“This new methodology was an incentive for
professionals already working in the area, which for
many years did not see any innovations in
tuberculosis. Then, the emergence of this new
methodology gave a new boost to many people.”
(Manager 1, Manaus)
“The satisfaction of employees as well, because for
them it was so … a very good thing for them. Just not
having to do 100 smears per day, 100 cultures.”
(Manager 3, Manaus)
One respondent also cited the benefits to worker’s
health:
“The emotional and psychological factors of the
workers who will be most pleased to do its work, will
get sick less often, take fewer licenses, will be less
prone to giving up working in that area. We saw a
great satisfaction.” (Manager 1, Manaus)
Biosafety issues and worker’s protection were also
mentioned:
“I think the main advantage [of the Xpert MTB/Rif]
refers to biosafety, the minimal structure that is
needed to perform the procedure with the equipment.
Just a workbench with plug, and it is sufficient to
install the equipment and do the exam. Unlike smears
that require a necessary structure, adequated to the
issues of biosafety, ventilation, a more adequate area.
(…) The worker protection, which is sometimes
required to work in a hazardous space, which does
not have the proper conditions, and even sometimes
does not receive all the necessary protective gear for
biosafety. This is very common, especially in the
countryside, where we see pathology technicians
doing sample preparation without masks in any sink,
in a hallway.” (Manager 2, Manaus)
Another issue highlighted was the reduction in re-
quired resources:
“If I performed 100 tests per day, I spent with the
previous method 200 slides because it requires two
samples. I needed to have dyes, slides, all doubled.
The material was doubled. Because I had to make two
samples (…) With the implementation of the ‘Gene’,
no, not only one sample was worked on. Then all the
required resources are reduced. If you do a test you
will not use anymore those dyes, all those things.
Why? The diagnosis is made directly on the machine.”
(Manager 3, Manaus)
Reducing the time of diagnosis was identified as an ad-
vantage of the new technology by respondents:
“With the implementation of the ‘Gene’ only one
sample became [necessary]. Then, the next day the
patient had the result, or we told the patient to wait,
he came to give us [the sample] in the morning and in
the afternoon he could check with us the result that
was already delivered. Before we did [the diagnosis] in
three days, 72 h. Why? Collect the first sample, collect
the second and 72 h have passed.” (Manager 3,
Manaus)
Respondents also emphasized the ease of training the
new technology:
“With smears, training is much more complicated,
you need a lab bench, you need a microscope, the
schedule for training is much more complex. And
with the automated equipment it would be an
automated thing and I believe training is very simple,
just operate the equipment.” (Manager 2, Manaus)
The cons of the new technology
Most of the interviewed managers had difficulties in
finding disadvantages in the new technology.
Sentences like “I see nothing against it” or “I only see
pros, no cons” were common:
“I personally can’t see any downside. Compared to
smears, I see nothing that I could say: 'Ah! It would
be better to stick to smears. I can’t see that,
particularly.” (Manager 2, Manaus)
However, some respondents mentioned the difficulty
of professionals at the front lines of health care to inter-
pret the results produced by the new technique:
“When you have a positive result from the ‘Gene’ and
a negative result from smear and do not qualify the
intensity with [a number of] crosses, people [health
care professionals] keep calling, they are in doubt.
They are trying to quantify the positive result, they
are used to it. Now there is no more quantification,
then they get concerned, thinking that the result is
wrong. We have to stop and explain. I mean, the lab
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loses time explaining to people how the test was done
and why it was not quantified.” (Manager 5, Rio)
One respondent highlighted the challenge of getting the
necessary funding for maintaning the new technology:
“The challenge is to get money to buy cartridges and
maintain what has been started. While there is still
resources left from this project it is assured, but after
that, which is unfortunate, is that we go back to the
same situation before, especially in facility X, which
has the highest demand of our state. There, the
problem is greater than anywhere. The downside is
this: how to get resources to ensure that it is kept in
the same proportion that was made during the
implementation of the project.” (Manager 1, Manaus)
The information system
Respondents in Rio de Janeiro were unanimous in saying
that the information system (GAL) presents itself as a
challenge, with implications for the agility of the results
produced by the new technology:
“We are in a phase of implementation of the GAL,
which is a Health Ministry system that allows web
access to all results, and this is not fully consolidated
as we would like. So the agility we expected with the
‘Gene’, I think in practice, we still need to improve the
use of the GAL system so that we actually get this
result.” (Manager 6, Rio)
Some managers mentioned that GAL lacks infrastruc-
ture to operate with full functionality:
“The problem of the system is that the [healthcare]
network is not completely structured in a way to work
online. So not all units achieve a good connectivity.
Do all of them have a computer? They all have. The
policlinic, for example, has computers, but I do not
have a computer in my office. I have no way to enter
a test requisition in my sample collection room. Then,
requisitions have to follow a flow in order to send this
request somewhere where there are computers, where
there’s good connectivity, so that we can enter the
data.” (Manager 5, Rio)
Another issue that arose was the fact that when the fa-
cilities are not capable of making a test request through
the system, they do not have access to the results
through the GAL:
“Not all units have the same structure. So, what
happens, we often receive samples in the laboratory
with the requisition on paper and not in the system.
Then, the laboratory has to enter the requisition and
the result. And often, the facility can’t see the result,
either. The GAL, I find it excellent, the problem is
having the structure in order to harness the full
potential of the system.” (Manager 5, Rio)
Despite the difficulties of infrastructure for the
operation of the GAL system, respondents stressed that
it is an important tool for the viability of new diagnostic
technologies:
“We knew that if we did not couple it [the new
diagnostic technology] with an information system
that made the test results flow, we would be doing a
compromised assessment. So, we anticipated some
issues. So we are not seeing, for example, as if a Rolls
Royce, which has the potential to run at 200 km/h,
but won’t be able to do so on a bumpy road. We
discussed and anticipated it, minimized this in the
deployment itself. And that way we did not create an
artificial thing, because the GAL is an Internet-based
system and what we did was to accelerate its
deployment so as to be able to address the issue of
implementing a new technology in an environment
that would not compromise our ability to evaluate.”
(Manager 1, Rio)
Changes in workflow
The new diagnostic technology resulted in a change in
the work process in the laboratory:
“The machine is considered a quick test, but it takes
actually two hours. The machines that we are working
with have four slots, then in fact the technician can
only put four tests to cycle every two hours. So it
ends up being a modifier in the work process in the
laboratory, since before, with smears, the technician
could arrive in the morning, stain all the slides and
read them throughout the day, and whoever stained
was not necessarily the person who would read.”
(Manager 1, Rio)
This manager clarifies that changes in work processes
are related to actions laboratory, not interfering in the
front lines:
“The technology is not disrupting work processes at
the front lines, that would be in fact more
complicated. That is, I’m taking samples in the same
way, I am forwarding samples in the same way, I’m
waiting for and getting samples within a system that
was already expected to receive, considering that the
GAL was about to be deployed despite the Xpert
project.” (Manager 1, Rio)
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“It was a new thing and it messed a little with the
structure of the laboratory, in the sense that people
needed training, and it was something that took quite
a while given the very activities that the ‘Gene’
required at that moment. And at that initial moment,
I had to suspend the routine work in the laboratory.
Routine tests, clinical analysis. So there was an
exclusive dedication to the ‘Gene’ due to our demand
here, which is immense.” (Manager 3, Manaus)
Respondents indicated that the new technology generated
a decrease in the work load of the laboratory:
“The other advantage is to reduce the load of work in
the laboratory. From the moment in which we work
with only one sample, we can organize ourselves
better for case detection. (…) The main change was in
the lab, the operationalization of the test, and
improving the workflow in the laboratory we can
further intensify this surveillance, because the lab will
respond to it. So when I had the smears, we limited
ourselves: ‘No, there is a quantity limit.’ Then we
restrict ourselves from making a more intense search
[for cases]. With the change of the lab, we have a
freer lab for us to have a larger number of persons to
be examined.” (Manager 2, Manaus)
In relation to changes in workflow, no resistance or
difficulties were identified in the interviews:
“There was no difficulty. It was very easy. People were
trained. It was very smooth.” (Manager 3, Rio)
One manager mentioned the good adaptation of the
technicians to the new technology:
“The machine software is in English, which is a
limitation, but as everything is very standardized, they
[technicians] have adapted very well.” (Manager 1, Rio)
Another interviewee even reported a fascination
produced by the machine:
“All technicians who are working there are
enchanted!” (Manager 3, Rio)
One respondent stated that technician satisfaction was
related to the fact that their routine work became more
similar to other laboratories working with computerized
systems:
“From what I saw of the satisfaction of technicians who
are already using it, it brings the routine of the
tuberculosis lab closer to the mode of operation of
other laboratory areas, which are automated and all
work already with computerized systems. Tuberculosis
was still somewhat apart, because it was the one that
had to perform a very old technique. So the technicians
were very happy to work with it.” (Manager 1, Rio)
Perspectives for the deployment of the new technology in
the public healthcare system (SUS)
The interviewees were unanimous in that the deploy-
ment of new technology in the SUS would bring benefits
for the diagnosis and treatment of TB:
“Our hypothesis is that the number of cases that are
going to be treated with definitive diagnosis will be
greater. Today we have around 50 % of patients who
start treating tuberculosis with a correct diagnosis.
We hope to increase this number which is certainly a
quality indicator for the Health Programme.”
(Manager 3, Rio)
“We will detect most cases, we will more adequately,
and consequently, we can avoid more deaths than we
have been able to do.” (Manager 1, Manaus)
“I believe it will be a breakthrough in the treatment of
tuberculosis, which is a disease that primarily affects
our county, Rio de Janeiro. So I believe that the city has
everything to gain with this new method, in advance of
multidrug resistance, resistance in tuberculosis. Already
having a diagnosis where the patient is detected if it is
resistant to some drugs or not, his treatment is
completely changed.” (Manager 2, Rio)
Respondents showed, however, concerns regarding the
necessary allocation of financial resources for the
maintenance of the new technology:
“Who will maintain [the new technology]? From
where will come the resources to keep it running? So,
this will depend a lot on pacts between the Federal
Government, states and municipalities. Maybe the
Ministry [of Health] will contribute with the
equipment and the municipalities will bear the costs
of the kits… I think it will depend on how this
conversation will be negotiated. I think the challenge
will be in the pacts, in defining this, because when it
comes to resources everybody tightens the strings of
the purse.” (Manager 2, Manaus)
Limitations of the study
The main limitation of the study is its context specificity;
the data collection was made in specific settings of two
cities in Brazil, and any conclusions and inferences are
limited by this. The selection of the sites, however, was
done in accordance to the high prevalence of TB, on the
one hand, and the different stages of implementation of
the new technology, which confers a degree of represen-
tativeness with regards to the situation of the Brazilian
healthcare system. Managers and professionals were
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purposefully selected in accordance to their relevance in
the sites, and can be considered representative in that
sense as well. Patients were selected by convenience, but
the utilization of the saturation criterion gives us confi-
dence that their views are also representative of the
users of public healthcare in the country.
Having said this, however, we believe that the lessons
learned from this specific process of implementation of
a new technology can at least inform researchers and
managers operating in similar contexts in understanding
the complex factors that influence the acceptance of
newly introduced technology.
Discussion
The acceptance and dissemination of a new technology
in health care is a non-linear process, that can be deter-
mined by a large array of factors, some linked to the
technology itself or the associated health problem,
others related to actions and interests of the different
stakeholders [10, 19]. Scientific evidence of a potential
superiority with regard to methods already in use is but
an element to influence the adoption of a new technol-
ogy. The capacity of organizations to incorporate new
knowledge and practice, the institutional, social and pol-
itical forces involved, and the perceptions and reasoning
of the various actors participating in the multiple arenas
where the incorporation of a new technology takes place
may induce specific patterns of acceptance or rejection
that need to be understood at a local level [20].
The incorporation of the new TB diagnostic technol-
ogy discussed in this study seems to be taking place
without much difficulty, but there are some limiting
factors to fully taking advantage of its benefits. The diffi-
culties with the online system echo observations made
in other studies about problems with health information
systems in general [21]. The low diffusion of the know-
ledge required for effective use of equipment and net-
works, the low availability of this resource type in public
and the very proliferation of systems that do not interact
with each other, often requiring the reinsertion of data
that should already be available, lead to bottlenecks in
the flow of information, which in our case even reflected
in the selection of patients for interview.
Selecting patients who had been diagnosed by the new
method demanded additional time, precisely because of
the difficulties still existing among health care workers
regarding access to the GAL. We view with concern the
adopted solution, both in Rio and Manaus, specifically
to designate an administrative staff member to enter
data into the system, repeating a tradition of restricting
the user interface of the system to a few administrative
professionals, when by design it should be accessible to
everyone involved.
This bottleneck can undermine one of the great advan-
tages of the system, which is its speed. We observed that
the practice of starting treatment with only the clinical
diagnosis still persists; unless laboratory confirmation is
available as soon as possible, this is unlikely to change.
Nevertheless, we did witness a few examples of the desired
change in clinical behavior. In interviews with managers
in Rio de Janeiro, a circumscribed problem also emerged,
in that certain doctors experienced difficulty to interpret
the results produced by the new technology. It should be
noted that, in general, even with quick access to test re-
sults, changes in medical conduct depend on a significant
investment in the continued education of these profes-
sionals, which should perhaps be considered more care-
fully in the routine rollout of the new system.
A particular problem in the case of Manaus is the long
time it takes patients to get to the testing facility, given
the local practice of referring patients to a centralized fa-
cility. Although this is an aspect linked to the specific
organization of public health services at that location,
not the testing technology per se, it is a factor that may
ultimately adversely impact the access to the test. Both
in Manaus and in Rio, displacement is facilitated by the
fact that patients are largely on medical leave, a contin-
gency that must also be considered in designing the
overall strategies to diagnose and treat TB in the general
population.
From the patients’ perspective, changes seem less no-
ticeable. The concerns that we have identified are linked
to the disease itself and its stigmas, and unlikely to be
impacted by any diagnostic technology.
The acceptance by managers was also wide and prac-
tically unrestricted, the only relevant question that arose
in the interviews was about the sustainability of long-
term use of the new technology. Given the uncertainties
that unfortunately persist with regards to SUS funding,
this is a relevant issue, but not specific to the adoption
of any given technology.
A particularly encouraging finding is the virtually un-
restricted acceptance of new technology by lab techni-
cians. Resistance at this level could jeopardize the
adoption of the new process, and we could not observe
any indication in that direction. From this particular
case, a general recommendation for the implementation
of new technologies could be derived: the participation
and empowerment of professionals directly involved is
critical. We can also speculate on the effect of positive
symbolic adoption of a technology in a field that has
spent decades without major innovations.
Other than that, although there are attempts in the
literature to systematize factors that can facilitate or
hinder the adoption of new technologies [11–13, 22–24],
it seems more likely that the specific reasons in each
case are more contingent than algorithmically predictable
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[25]. Rogers [26] describes some of the attributes of an
innovation that can favor its successful incorporation: com-
parative advantages with regard to preexisting technologies;
reduced complexity; compatibility with values, needs and
current practices within organizations; opportunities for
experimentation offered by the new technology; visibility of
results of the new technology to its users. Other authors
emphasize evidence as a factor that works in favor of the
acceptance of the new technology, but what constitutes
“evidence” can vary across different groups [27]. In this
particular case, pragmatic and cultural factors played a
significant role, namely, making work in the laboratory
easier but still within control of the technicians, and the
relative fascination with “new” things. Kulviwat et al.’s
suggestion that self-efficacy also plays a role in technology
acceptance [28] may apply here as well, at least in the case
of the lab technicians. Available evidence of the intrinsic
qualities of the new technology, on the other hand, was not
enough to make physicians change their routine of starting
treatment before laboratory confirmation.
Conclusion
In summary, the introduction of the new technology has
been widely accepted and is viewed very positively by
those involved, especially laboratory technicians. The
process of adoption itself was also uneventful and did not
face major barriers by managers or health professionals.
Most of the difficulties encountered are more attributable
to contextual conditions than to the technology itself, but
must in any case be considered for its expansion through-
out the national SUS network.
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